A Win Ratio analysis confirmed the primary result of the NOAH—AFNET 6 trial and did not find an advantage of anticoagulation with edoxaban over no anticoagulation in patients with device-detected ...

Newer Blood Thinner Cuts Odds for Stroke After Heart Valve Surgery By Carole Tanzer Miller HealthDay Reporter TUESDAY, Nov. 19, 2024 (HealthDay News) -- Japanese researchers say they have found a pill ...

CHICAGO, IL—Following bioprosthetic valve surgery, anticoagulation with edoxaban (Savaysa; Daiichi Sankyo) is as effective as warfarin, although this strategy might come at a higher cost of bleeding, ...

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial ...

London, United Kingdom – 1 September 2024: Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic ...

The Subject Expert Committee (SEC), which advises the national drug regulator on approval of drugs, new drugs and clinical trials, has recommended grant of permission to Maharashtra-based Zuventus ...

Data from more than 13,000 patients with AF show that the use of edoxaban over four years is associated with a low annualised rate of all-cause death, ischaemic stroke and major bleeding. 1, 2 The ...

Researchers found that the anticoagulant effects of apixaban, betrixaban, edoxaban, and rivaroxaban were partially neutralized at an andexanet alfa dose of 50 mcg/mL and were completely neutralized at ...

In the ENNOBLE-ATE trial, Michael A. Portman, MD, FAHA, director, Pediatric Cardiovascular Research, Center for Integrative Brain Research, and professor of pediatrics at Seattle Children's, and his ...

Treatment with the direct factor Xa inhibitor edoxaban (Lixiana) resulted in low rates of clinically relevant bleeding and thromboembolism (TE) compared with standard-of-care (SOC) anticoagulants in ...

Data from a multivariate analysis of the ETNA-AF registry show that for AF patients with diabetes mellitus (DM) treated with edoxaban, the insulin treated DM patients were associated with an increased ...